Azeria Therapeutics is Drug Discovery in United Kingdom that focus on medical professionals business. Founded in 2017. They cover business area such as developer, small-molecule pipeline device, breast and prostate cancer, treatment, hormone-resistant breast cancer patient, significant area, unmet clinical need, pioneer factor, healthcare organization, medical professional, multiple cancer type.
2017
( 7 years old in 2024 )
Medical Professionals
-
CRUK Cambridge Institute
Robinson Way
Cambridge CB2 0RE
England, United Kingdom
Private
developersmall-molecule pipeline devicebreast and prostate cancertreatmenthormone-resistant breast cancer patientsignificant areaunmet clinical needpioneer factorhealthcare organizationmedical professionalmultiple cancer type
* We use standard office opening hours in near Azeria Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Azeria Therapeutics is Drug Discovery business from United Kingdom that founded in 2017 (7 years old in 2024), Azeria Therapeutics business is focusing on Medical Professionals.
Azeria Therapeutics headquarter office and corporate office address is located in CRUK Cambridge Institute Robinson Way Cambridge CB2 0RE England, United Kingdom.
Azeria Therapeutics was founded in United Kingdom.
In 2024, Azeria Therapeutics is currently focus on medical professionals sector.
Above is snippet of Google Trends for "medical professionals" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Azeria Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
